- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05433168
Study Evaluating the Effectiveness of Shiatsu on Fatigue in Patients With Axial Spondyloarthritis (SFASPA)
Randomized Cross-over Pilot Study Evaluating the Effectiveness of Shiatsu on Fatigue in Patients With Axial Spondyloarthritis
Spondyloarthritis is a potentially serious disease with reduced life expectancy. Even if the clinical presentation is eminently variable from one patient to another, the most frequently encountered manifestations such as inflammatory spinal pain, peripheral arthritis or even extra-articular involvement of the disease all represent disabling symptoms, origin of pain, temporary or in some cases permanent functional incapacity, but also general repercussions on daily life (asthenia, reactive depressive syndrome, etc.) which require a multidisciplinary approach, involving several medical, paramedical and other stakeholders, The objective of treatment is to improve quality of life, to control symptoms and inflammation, to prevent structural damage, particularly in peripheral damage, to preserve or restore functional capacities, autonomy and social participation of patients with spondyloarthritis.
In France, the main professional reference for shiatsu is the Syndicat des Professionnels de Shiatsu, which proposes the following definition to define shiatsu:
Shiatsu (finger pressure in Japanese) is an energetic manual discipline addressing the individual as a whole. Shiatsu is part of personal assistance. He receives himself, dressed in soft clothes. Shiatsu is a discipline of well-being and prevention for better health. Its objective is to correct both the energy flow (ki, blood, lymph, etc.) and the body structure (muscles, tendons, etc.) by applying rhythmic pressure to the whole body, most often with the inches. It is for everyone and at all ages. Its principle of action is to restore the free flow of Ki (qi, Energy) in the body.
Shiatsu is a set of pressures performed mainly with the thumbs and the palms of the hands on different areas of the body, often taking up the points of the acupuncture meridians. Shiatsu pressures can be (Ishizuka 1993; Kagotani 1984; Okamoto 2016):
- mobile in a given place and lasting 3 to 5 seconds: a phase of increasing pressure followed by a short holding time then release,
- static: same phases but with a hold time of up to approximately 1 minute or even longer.
To date, there is no treatment specifically targeting fatigue in axSpA. Indeed, the underlying mechanisms of fatigue in SpA remain poorly understood, and could for example involve pro-inflammatory cytokines and the inflammatory process, and/or psychological distress. The effectiveness of non-pharmacological interventions and in particular the care provided by shiatsu practitioners have not been the subject of studies evaluating, according to the criteria of evidence-based medicine, the benefit of this practice, particularly in the context of treatment of spondyloarthritis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To investigate the variations in the fatigue score (FACIF-F) after a shiatsu intervention (3 sessions) versus a sham shiatsu intervention (3 sessions) (control group).
The primary endpoint will be the percentage of patients responding to the FACIT Fatigue score. A response to fatigue will be defined as an improvement, i.e. an increase of ≥ 4 points in the FACIT-F score corresponding to the minimum clinically important difference.
Monocentric randomized controlled cross-over trial with allocation of patients according to a ratio (1:1) The study will be offered prospectively and systematically to patients with spondyloarthritis meeting the inclusion criteria during a follow-up consultation or in a day hospital or traditional hospitalization in the rheumatology department.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Orléans, France, 45067
- CHU Orléans
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patients with spondyloarthritis meeting the ASAS criteria and followed in the rheumatology department of the Orléans Regional Hospital Center.
- Men and women aged 18 to 70
- Patients with digital or visual analog rating scale ≥ 3 on the 1st question of the BASDAI
Exclusion Criteria:
- Patient with a pathology that contraindicates the practice of shiatsu (evolving infectious skin pathology that would make shiatsu treatment difficult)
- Previous shiatsu treatment
- Inability to attend appointments for the duration of the study
- Pregnant or breastfeeding woman
- Refusal to participate in the study or to sign the consent
- Patients not affiliated or not beneficiaries of a social security scheme
- Person under guardianship or curatorship
- Patient with an uncontrolled epileptic or psychotic condition which, in the opinion of the investigator, would interfere with the smooth running of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: SHIATSU GROUP
The patients will benefit from shiatsu treatments by a professional according to the shiatsu protocol developed by the Syndicate's evaluation commission Shiatsu Professionals (SPS).
|
The patients will benefit from shiatsu treatments by a professional according to the shiatsu protocol developed by the Syndicate's evaluation commission Shiatsu Professionals (SPS).
Exercising a fake shiatsu is a real problem as opinions differ.
The consensus of the different schools and styles of the technique is that shiatsu pressure is weight transfer.
We are therefore going to remove this aspect from the SFASPA shiatsu protocol.
The professional will run the same sequence of points, without any weight transfer, being only in contact with the receiver
|
|
Experimental: DUMMY SHIATSU GROUP
Exercising a fake shiatsu is a real problem as opinions differ.
The consensus of the different schools and styles of the technique is that shiatsu pressure is weight transfer.
We are therefore going to remove this aspect from the SFASPA shiatsu protocol.
The professional will run the same sequence of points, without any weight transfer, being only in contact with the receiver.
|
The patients will benefit from shiatsu treatments by a professional according to the shiatsu protocol developed by the Syndicate's evaluation commission Shiatsu Professionals (SPS).
Exercising a fake shiatsu is a real problem as opinions differ.
The consensus of the different schools and styles of the technique is that shiatsu pressure is weight transfer.
We are therefore going to remove this aspect from the SFASPA shiatsu protocol.
The professional will run the same sequence of points, without any weight transfer, being only in contact with the receiver
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of patients responding to the FACIT Fatigue score
Time Frame: Day 0
|
A response to fatigue will be defined as an improvement, i.e. an increase of ≥ 4 points in the FACIT-F score corresponding to the minimum clinically important difference. It is a short, easy to administer, 13-item tool that measures a person's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point Likert scale (4 = not at all tired to 0 = very tired) |
Day 0
|
|
Percentage of patients responding to the FACIT Fatigue score
Time Frame: Day 14
|
A response to fatigue will be defined as an improvement, i.e. an increase of ≥ 4 points in the FACIT-F score corresponding to the minimum clinically important difference. It is a short, easy to administer, 13-item tool that measures a person's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point Likert scale (4 = not at all tired to 0 = very tired) |
Day 14
|
|
Percentage of patients responding to the FACIT Fatigue score
Time Frame: Day 28
|
A response to fatigue will be defined as an improvement, i.e. an increase of ≥ 4 points in the FACIT-F score corresponding to the minimum clinically important difference. It is a short, easy to administer, 13-item tool that measures a person's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point Likert scale (4 = not at all tired to 0 = very tired) |
Day 28
|
|
Percentage of patients responding to the FACIT Fatigue score
Time Frame: Day 35
|
A response to fatigue will be defined as an improvement, i.e. an increase of ≥ 4 points in the FACIT-F score corresponding to the minimum clinically important difference. It is a short, easy to administer, 13-item tool that measures a person's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point Likert scale (4 = not at all tired to 0 = very tired) |
Day 35
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global Pain Evaluation (EVN)
Time Frame: Day 0
|
The EVA pain scale is a graduated ruler ranging from 0 to 10. 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit.
Show the differences in disease progression between the 2 treatment arms
|
Day 0
|
|
Global Pain Evaluation (EVN)
Time Frame: Day 3
|
The EVA pain scale is a graduated ruler ranging from 0 to 10. 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit.
Show the differences in disease progression between the 2 treatment arms
|
Day 3
|
|
Global Pain Evaluation (EVN)
Time Frame: Day 14
|
The EVA pain scale is a graduated ruler ranging from 0 to 10. 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit.
Show the differences in disease progression between the 2 treatment arms
|
Day 14
|
|
Global Pain Evaluation (EVN)
Time Frame: Day 18
|
The EVA pain scale is a graduated ruler ranging from 0 to 10. 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit.
Show the differences in disease progression between the 2 treatment arms
|
Day 18
|
|
Global Pain Evaluation (EVN)
Time Frame: Day 28
|
The EVA pain scale is a graduated ruler ranging from 0 to 10. 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit.
Show the differences in disease progression between the 2 treatment arms
|
Day 28
|
|
Global Pain Evaluation (EVN)
Time Frame: Day 35
|
The EVA pain scale is a graduated ruler ranging from 0 to 10. 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit.
Show the differences in disease progression between the 2 treatment arms
|
Day 35
|
|
Global Pain Evaluation (EVN)
Time Frame: Day 56
|
The EVA pain scale is a graduated ruler ranging from 0 to 10. 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit.
Show the differences in disease progression between the 2 treatment arms
|
Day 56
|
|
BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)
Time Frame: Day 0
|
This is a questionnaire to calculate the activity index of ankylosing spondylitis. The intensity of 5 symptoms during the past week will be estimated, giving a score from 0 to 10, knowing that 0 means the absence of the symptom and 10 its presence in the highest degree 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. |
Day 0
|
|
BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)
Time Frame: Day 3
|
This is a questionnaire to calculate the activity index of ankylosing spondylitis. The intensity of 5 symptoms during the past week will be estimated, giving a score from 0 to 10, knowing that 0 means the absence of the symptom and 10 its presence in the highest degree 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. |
Day 3
|
|
BASDAI Bath Ankylosing Spondylitis Disease Activity Index
Time Frame: Day 14
|
This is a questionnaire to calculate the activity index of ankylosing spondylitis. The intensity of 5 symptoms during the past week will be estimated, giving a score from 0 to 10, knowing that 0 means the absence of the symptom and 10 its presence in the highest degree 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. |
Day 14
|
|
BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)
Time Frame: Day 18
|
This is a questionnaire to calculate the activity index of ankylosing spondylitis. The intensity of 5 symptoms during the past week will be estimated, giving a score from 0 to 10, knowing that 0 means the absence of the symptom and 10 its presence in the highest degree 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. |
Day 18
|
|
BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)
Time Frame: Day 28
|
This is a questionnaire to calculate the activity index of ankylosing spondylitis. The intensity of 5 symptoms during the past week will be estimated, giving a score from 0 to 10, knowing that 0 means the absence of the symptom and 10 its presence in the highest degree 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. |
Day 28
|
|
BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)
Time Frame: Day 35
|
This is a questionnaire to calculate the activity index of ankylosing spondylitis. The intensity of 5 symptoms during the past week will be estimated, giving a score from 0 to 10, knowing that 0 means the absence of the symptom and 10 its presence in the highest degree 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. |
Day 35
|
|
BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)
Time Frame: Day 56
|
This is a questionnaire to calculate the activity index of ankylosing spondylitis. The intensity of 5 symptoms during the past week will be estimated, giving a score from 0 to 10, knowing that 0 means the absence of the symptom and 10 its presence in the highest degree 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. Show the differences in disease progression between the 2 treatment arms |
Day 56
|
|
BASFI questionnaire (Bath ankylosing spondylitis functional index)
Time Frame: Day 0
|
It was developed specifically to assess joint mobility in SpA. The BASFI reflects the functional impact, that is to say the inability to perform actions of daily life. For each of the ten activities, you must rate from 0 to 10 the ease or difficulty of performing them during the past month. 0 means completely easy, 10 means impossible. This score is an aid in monitoring ankylosing spondylitis. Show the differences in disease progression between the 2 treatment arms |
Day 0
|
|
BASFI questionnaire (Bath ankylosing spondylitis functional index)
Time Frame: Day 14
|
It was developed specifically to assess joint mobility in SpA. The BASFI reflects the functional impact, that is to say the inability to perform actions of daily life. For each of the ten activities, you must rate from 0 to 10 the ease or difficulty of performing them during the past month. 0 means completely easy, 10 means impossible. This score is an aid in monitoring ankylosing spondylitis. Show the differences in disease progression between the 2 treatment arms |
Day 14
|
|
BASFI questionnaire (Bath ankylosing spondylitis functional index)
Time Frame: Day 28
|
It was developed specifically to assess joint mobility in SpA. The BASFI reflects the functional impact, that is to say the inability to perform actions of daily life. For each of the ten activities, you must rate from 0 to 10 the ease or difficulty of performing them during the past month. 0 means completely easy, 10 means impossible. This score is an aid in monitoring ankylosing spondylitis. Show the differences in disease progression between the 2 treatment arms |
Day 28
|
|
BASFI questionnaire (Bath ankylosing spondylitis functional index)
Time Frame: Day 35
|
It was developed specifically to assess joint mobility in SpA. The BASFI reflects the functional impact, that is to say the inability to perform actions of daily life. For each of the ten activities, you must rate from 0 to 10 the ease or difficulty of performing them during the past month. 0 means completely easy, 10 means impossible. This score is an aid in monitoring ankylosing spondylitis. Show the differences in disease progression between the 2 treatment arms |
Day 35
|
|
Short Form-36 (SF-36)
Time Frame: Day 0
|
It is a self-assessment quality of life scale comprising 11 questions Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: |
Day 0
|
|
Short Form-36
Time Frame: Day 14
|
It is a self-assessment quality of life scale comprising 11 questions Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: |
Day 14
|
|
Short Form-36
Time Frame: Day 28
|
It is a self-assessment quality of life scale comprising 11 questions. Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: |
Day 28
|
|
Short Form-36
Time Frame: Day 35
|
It is a self-assessment quality of life scale comprising 11 questions. Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: |
Day 35
|
|
AsQoL Questionnaire (Ankylosing Spondylitis Quality of Life Questionnaire)
Time Frame: Day 0
|
Score validated in French in 2010(Pham et al. 2010), it is composed of 18 double-choice (yes/no) items.
All the points obtained are added together and divided by the maximum possible total Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: AS Quality of Life (ASQOL)
|
Day 0
|
|
AsQoL Questionnaire (Ankylosing Spondylitis Quality of Life Questionnaire)
Time Frame: Day 14
|
Score validated in French in 2010(Pham et al. 2010), it is composed of 18 double-choice (yes/no) items.
All the points obtained are added together and divided by the maximum possible total Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: AS Quality of Life (ASQOL)
|
Day 14
|
|
AsQoL Questionnaire (Ankylosing Spondylitis Quality of Life Questionnaire)
Time Frame: Day 28
|
Score validated in French in 2010(Pham et al. 2010), it is composed of 18 double-choice (yes/no) items.
All the points obtained are added together and divided by the maximum possible total Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: AS Quality of Life (ASQOL)
|
Day 28
|
|
AsQoL Questionnaire (Ankylosing Spondylitis Quality of Life Questionnaire)
Time Frame: Day 35
|
Score validated in French in 2010(Pham et al. 2010), it is composed of 18 double-choice (yes/no) items.
All the points obtained are added together and divided by the maximum possible total Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: AS Quality of Life (ASQOL)
|
Day 35
|
|
BASMI measurement index
Time Frame: Day 0
|
It allows to evaluate the mobility of the spine.
It is composed of 5 items including: cervical rotation, tragus wall distance, lateral flexion of the spine, lumbar flexion and inter malleolar distance.
The score for each item is added together to result in a rating out of 10.
|
Day 0
|
|
BASMI measurement index
Time Frame: Day 35
|
It allows to evaluate the mobility of the spine.
It is composed of 5 items including: cervical rotation, tragus wall distance, lateral flexion of the spine, lumbar flexion and inter malleolar distance.
The score for each item is added together to result in a rating out of 10.
|
Day 35
|
|
SpA Patient Health Index (ASAS Health Index)
Time Frame: Day 0
|
This self-assessment questionnaire measures functioning and health across 17 aspects of health and 9 environmental factors (EFs) in patients with SpA.
The ASAS HI contains items covering the following categories: pain, emotional functions, sleep, sexual functions, mobility, autonomy and community life
|
Day 0
|
|
SpA Patient Health Index (ASAS Health Index)
Time Frame: Day 14
|
This self-assessment questionnaire measures functioning and health across 17 aspects of health and 9 environmental factors (EFs) in patients with SpA.
The ASAS HI contains items covering the following categories: pain, emotional functions, sleep, sexual functions, mobility, autonomy and community life
|
Day 14
|
|
SpA Patient Health Index (ASAS Health Index)
Time Frame: Day 28
|
This self-assessment questionnaire measures functioning and health across 17 aspects of health and 9 environmental factors (EFs) in patients with SpA.
The ASAS HI contains items covering the following categories: pain, emotional functions, sleep, sexual functions, mobility, autonomy and community life
|
Day 28
|
|
SpA Patient Health Index (ASAS Health Index)
Time Frame: Day 35
|
This self-assessment questionnaire measures functioning and health across 17 aspects of health and 9 environmental factors (EFs) in patients with SpA.
The ASAS HI contains items covering the following categories: pain, emotional functions, sleep, sexual functions, mobility, autonomy and community life
|
Day 35
|
|
Work Productivity Index (WPAI) (Work Productivity and activity Impairment questionnaire)
Time Frame: Day 0
|
This is a self-administered questionnaire where the assessment is based on the patient's absenteeism, his presence and his difficulties in carrying out his work or his outside activities.
The higher the score, the more the patient has difficulty
|
Day 0
|
|
Work Productivity Index (WPAI) (Work Productivity and activity Impairment questionnaire)
Time Frame: Day 14
|
This is a self-administered questionnaire where the assessment is based on the patient's absenteeism, his presence and his difficulties in carrying out his work or his outside activities.
The higher the score, the more the patient has difficulty
|
Day 14
|
|
Work Productivity Index (WPAI) (Work Productivity and activity Impairment questionnaire)
Time Frame: Day 28
|
This is a self-administered questionnaire where the assessment is based on the patient's absenteeism, his presence and his difficulties in carrying out his work or his outside activities.
The higher the score, the more the patient has difficulty
|
Day 28
|
|
Work Productivity Index (WPAI) (Work Productivity and activity Impairment questionnaire)
Time Frame: Day 35
|
This is a self-administered questionnaire where the assessment is based on the patient's absenteeism, his presence and his difficulties in carrying out his work or his outside activities.
The higher the score, the more the patient has difficulty
|
Day 35
|
|
Anxiety and Depression (HAD) scale
Time Frame: Day 0
|
The HAD scale is an instrument used to screen for anxiety and depressive disorders.
It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus allowing two scores to be obtained (maximum score for each score = 21)
|
Day 0
|
|
Anxiety and Depression (HAD) scale
Time Frame: Day 14
|
The HAD scale is an instrument used to screen for anxiety and depressive disorders.
It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus allowing two scores to be obtained (maximum score for each score = 21)
|
Day 14
|
|
Anxiety and Depression (HAD) scale
Time Frame: Day 28
|
The HAD scale is an instrument used to screen for anxiety and depressive disorders.
It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus allowing two scores to be obtained (maximum score for each score = 21)
|
Day 28
|
|
Anxiety and Depression (HAD) scale
Time Frame: Day 35
|
The HAD scale is an instrument used to screen for anxiety and depressive disorders.
It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus allowing two scores to be obtained (maximum score for each score = 21)
|
Day 35
|
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Day 0
|
This index is used to assess the sleep quality of subjects over the past month. The 17 scoring items in this study were combined into six components: sleep quality, time to fall asleep, sleep time, sleep efficiency, sleep disorder, and daytime dysfunction. Each component used a Likert4 score (scored from 0 to 3), and the scores were added to obtain a total of 0-21 points. The higher the PSQI index, the worse the quality of sleep. A PSQI >7 is considered indicative of a sleep disorder. |
Day 0
|
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Day 14
|
This index is used to assess the sleep quality of subjects over the past month. The 17 scoring items in this study were combined into six components: sleep quality, time to fall asleep, sleep time, sleep efficiency, sleep disorder, and daytime dysfunction. Each component used a Likert4 score (scored from 0 to 3), and the scores were added to obtain a total of 0-21 points. The higher the PSQI index, the worse the quality of sleep. A PSQI >7 is considered indicative of a sleep disorder. |
Day 14
|
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Day 28
|
This index is used to assess the sleep quality of subjects over the past month. The 17 scoring items in this study were combined into six components: sleep quality, time to fall asleep, sleep time, sleep efficiency, sleep disorder, and daytime dysfunction. Each component used a Likert4 score (scored from 0 to 3), and the scores were added to obtain a total of 0-21 points. The higher the PSQI index, the worse the quality of sleep. A PSQI >7 is considered indicative of a sleep disorder. |
Day 28
|
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Day 35
|
This index is used to assess the sleep quality of subjects over the past month. The 17 scoring items in this study were combined into six components: sleep quality, time to fall asleep, sleep time, sleep efficiency, sleep disorder, and daytime dysfunction. Each component used a Likert4 score (scored from 0 to 3), and the scores were added to obtain a total of 0-21 points. The higher the PSQI index, the worse the quality of sleep. A PSQI >7 is considered indicative of a sleep disorder. |
Day 35
|
Collaborators and Investigators
Investigators
- Principal Investigator: Eric LESPESSAILLES, PH, CHR d'Orléans
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bone Diseases
- Musculoskeletal Diseases
- Arthritis
- Joint Diseases
- Spinal Diseases
- Spondylarthropathies
- Ankylosis
- Spondylitis
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Axial Spondyloarthritis
- Spondylarthritis
- Fatigue
- Therapeutics
- Complementary Therapies
- Physical Therapy Modalities
- Rehabilitation
- Therapy, Soft Tissue
- Musculoskeletal Manipulations
- Acupressure
Other Study ID Numbers
- CHRO-2021-14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spondyloarthritis
-
University of BonnNovartis; Novartis PharmaceuticalsRecruitingAxial Spondyloarthritis | Axial and Peripheral Spondyloarthritis | Axial Spondyloarthopathy | Axial Spondyloarthritis and Ankylosing Spondylitis | Axial Spondyloarthritis (AxSpA) | Axial Spondylarthritis (r-axSpA) | Axial Spondyloarthritis, Non-RadiographicGermany
-
Lingli DongNot yet recruitingNon-Radiographical Axial Spondyloarthritis | Nr-axial SpondyloarthritisChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.RecruitingA Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial SpondyloarthritisActive Non-radiographic Axial SpondyloarthritisChina
-
UCB Biopharma SRLCompletedNonradiographic Axial SpondyloarthritisUnited States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Poland, Spain, United Kingdom, Turkey (Türkiye)
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Not yet recruitingAxial Spondyloarthritis, Non-RadiographicChina
-
Novartis PharmaceuticalsActive, not recruitingNon-radiographic Axial SpondyloarthritisItaly, Germany, Thailand, Israel, Belgium, France, Hungary, Malaysia, Poland, Philippines, Colombia, Mexico, Romania, Czechia, Brazil, Netherlands, Vietnam, Turkey (Türkiye)
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...RecruitingAxial SpondyloarthritisChina
-
Merck Sharp & Dohme LLCCompletedSpondyloarthritisCzechia, Germany, Netherlands, Poland, Romania, Russian Federation, Spain, Turkey, Ukraine
-
Novartis PharmaceuticalsCompletedNon-radiographic Axial SpondyloarthritisChina
-
UCB Biopharma SRLActive, not recruitingAnkylosing Spondylitis | Axial Spondyloarthritis | r-axSpa | Nr-axSpaUnited States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Netherlands, Poland, Spain, United Kingdom, Turkey (Türkiye)
Clinical Trials on SHIATSU
-
University of Sao Paulo General HospitalCompleted
-
Assistance Publique - Hôpitaux de ParisAssociation Française Contre l'Amylose (association of patients and families...Recruiting
-
Universidade Cidade de Sao PauloCompletedOccupational Diseases | Work-related InjuryBrazil
-
The Chaim Sheba Medical CenterWithdrawnQuality of Life | Radiation Toxicity | Chemotherapeutic Toxicity
-
Tel Aviv UniversityTel Aviv Sourasky Medical Center, Tel Aviv, Israel; Dana-Dwek Children's HospitalRecruitingChronic Pain | Fibromyalgia | Chronic Pain Syndrome | Fibromyalgia Syndrome | Chronic Pain, Widespread | Chronic Pain and Comorbid Emotional Problems | Chronic Pain, Psychogenic | Functional PainIsrael
-
Universidade Federal do vale do São FranciscoRecruitingDepression | Anxiety | Depressive SymptomsBrazil
-
Norton Thoracic InstituteRecruiting